直接抗病毒药物清除丙型肝炎病毒可改善严重肝纤维化患者的颈动脉粥样硬化
研究纳入182例丙型肝炎病毒(HCV)感染伴进展期纤维化或代偿期肝硬化患者,均接受直接抗病毒药物(DAA)治疗并全部获得持续病毒学应答。治疗后9-12个月颈动脉内膜中层厚度(IMT)和颈动脉增厚患病率较基线显著降低,颈动脉斑块无显著变化。作者认为DAA清除HCV可改善严重纤维化患者的颈动脉粥样硬化,其对主要心血管结局的影响值得长期研究。
要点
- DAA治疗清除HCV后,颈动脉IMT从基线0.94±0.29 mm降至0.81±0.27 mm(p<0.001)。
- 颈动脉增厚(IMT≥1 mm)患病率从基线42.8%降至随访17%(p<0.001)。
- 颈动脉斑块患病率基线42.8% vs 随访47.8%(p=0.34),无显著变化。
核心结论
- DAA清除HCV可改善严重肝纤维化伴或不伴代谢危险因素患者的颈动脉粥样硬化。
- 作者认为这种动脉粥样硬化负荷改善对主要心血管结局的影响值得长期研究。
研究设计与样本
- 研究纳入182例连续HCV感染伴进展期纤维化或代偿期肝硬化患者。
- 所有患者按AISF/EASL指南接受基于DAA的抗病毒治疗。
- 基线及治疗结束后9-12个月行超声评估颈动脉IMT、颈动脉增厚(IMT≥1 mm)和颈动脉斑块(颈总动脉水平局限性增厚≥1.5 mm)。
主要发现
- 全部患者获得12周持续病毒学应答。
- 颈动脉IMT从基线0.94±0.29 mm降至随访0.81±0.27 mm(p<0.001)。
- 颈动脉增厚患病率从基线42.8%降至随访17%(p<0.001)。
- 颈动脉斑块患病率基线42.8% vs 随访47.8%(p=0.34),无显著变化。
- 按心血管危险因素和肝病严重程度分层的亚组中上述结果得到确认。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recent studies suggest an association between hepatitis C virus (HCV) infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct-acting antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. MATERIALS AND METHODS: One hundred eighty-two consecutive patients with HCV and advanced fibrosis or compensated cirrhosis were evaluated. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickness (IMT), carotid thickening (IMT ≥1 mm) and carotid plaques, defined as focal thickening of ≥1.5 mm at the level of the common carotid, were evaluated by ultrasonography (US) at baseline and 9-12 months after the end of therapy. Fifty-six percent of patients were male, mean age 63.1 ± 10.4 years, and 65.9% had compensated cirrhosis. One in five had diabetes, 14.3% were obese, 41.8% had arterial hypertension and 35.2% were smokers. At baseline, mean IMT was 0.94 ± 0.29 mm, 42.8% had IMT ≥1 mm, and 42.8% had carotid plaques. RESULTS: All patients achieved a 12-week sustained virological response. IMT significantly decreased from baseline to follow-up (0.94 ± 0.29 mm vs. 0.81 ± 0.27, p <0.001). Consistently, a significant reduction in the prevalence of patients with carotid thickening from baseline to follow-up was observed (42.8% vs. 17%, p <0.001), while no changes were reported for carotid plaques (42.8% vs. 47.8%, p = 0.34). These results were confirmed in subgroups of patients stratified for cardiovascular risk factors and liver disease severity. CONCLUSION: HCV eradication by DAA improves carotid atherosclerosis in patients with severe fibrosis with or without additional metabolic risk factors. The impact of this improvement in the atherosclerotic burden in terms of reduction of major cardiovascular outcomes is worth investigating in the long term. LAY SUMMARY: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. The improvement in intima-media thickness and carotid thickening was confirmed after stratification for severity of liver disease and cardiovascular risk factors. Hepatitis C virus eradication by direct-acting antiviral agents also lead to improvement in glucose homeostasis and increased cholesterol levels.
引用
- Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018. PMID: 29505844. doi:10.1016/j.jhep.2018.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。